Nitazoxanide CR is under clinical development by Romark Laboratories LC and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Genfit S.A. (NASDAQ:GNFT – Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 59,800 shares, ...

Competing Interests: The author has been involved in clinical trials of albendazole and nitazoxanide, and has received research funding for these trials from SmithKline Beecham Pharmaceuticals and ...

[19] The broad-spectrum antiparasitic activity of nitazoxanide means that it could be used as 'blind' therapy in those parts of the world where laboratory diagnostic facilities are not affordable ...

Tevogen Bio (NASDAQ:TVGN – Get Free Report) and Genfit (NASDAQ:GNFT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses ...

"Versantis has an exciting portfolio that is complementary to Genfit's," Prigent told investors, pointing to its own nitazoxanide (NTZ) candidate, which has phase 1 data in hand and is also being ...

At close: 23 December at 17:35:13 CET ...